Joanna Moncrieff
@joannamoncrieff.bsky.social
Critical psychiatrist, professor at University College London and author. Views are my own.
Reposted by Joanna Moncrieff
When Dr. Roussos-Ross pointed out the dangers of untreated depression, she left out the fact that antidepressants (ADs) have modest efficacy (as later pointed out by @joannamoncrieff.bsky.social ). Bc of the side effects, ADs are associated with a problematic harm-benefit ratio for the majority.
July 28, 2025 at 2:56 PM
When Dr. Roussos-Ross pointed out the dangers of untreated depression, she left out the fact that antidepressants (ADs) have modest efficacy (as later pointed out by @joannamoncrieff.bsky.social ). Bc of the side effects, ADs are associated with a problematic harm-benefit ratio for the majority.
Reposted by Joanna Moncrieff
Occurrence of a discontinuation syndrome in the 5-8 day discontinuation period, defined by Rosenbaum et al. as 4+ withdrawal symptoms: 60% sertraline, 66%paroxetine, and 14% fluoxetine (which can serve as control group).
This conforms the ca. 50% occurrence, which was dismissed by Hayes 🤔
This conforms the ca. 50% occurrence, which was dismissed by Hayes 🤔
July 13, 2025 at 9:02 AM
Occurrence of a discontinuation syndrome in the 5-8 day discontinuation period, defined by Rosenbaum et al. as 4+ withdrawal symptoms: 60% sertraline, 66%paroxetine, and 14% fluoxetine (which can serve as control group).
This conforms the ca. 50% occurrence, which was dismissed by Hayes 🤔
This conforms the ca. 50% occurrence, which was dismissed by Hayes 🤔
Reposted by Joanna Moncrieff
Reposted by Joanna Moncrieff
Also note that the SMD's for individual SSRI/SNRI's ranged between 0.39 and 0.68.
In the study of Rosenbaum, where patients were on antidepressants much longer (average ca. 11 months), the increase in DESS symptoms after stopping meds was 6 and 8 for sertraline and paroxetine, respectively.
In the study of Rosenbaum, where patients were on antidepressants much longer (average ca. 11 months), the increase in DESS symptoms after stopping meds was 6 and 8 for sertraline and paroxetine, respectively.
July 13, 2025 at 7:54 AM
Also note that the SMD's for individual SSRI/SNRI's ranged between 0.39 and 0.68.
In the study of Rosenbaum, where patients were on antidepressants much longer (average ca. 11 months), the increase in DESS symptoms after stopping meds was 6 and 8 for sertraline and paroxetine, respectively.
In the study of Rosenbaum, where patients were on antidepressants much longer (average ca. 11 months), the increase in DESS symptoms after stopping meds was 6 and 8 for sertraline and paroxetine, respectively.
Reposted by Joanna Moncrieff
Besides the double standards, the main problem is that the result from the main analysis is based on short-term trials (ca 8w) except one 26w agomelatine trial. Not much withdrawal can be expected but was nonetheless observed - concerning! Most are on ADs much longer. Absurd conclusions!
July 13, 2025 at 7:12 AM
Besides the double standards, the main problem is that the result from the main analysis is based on short-term trials (ca 8w) except one 26w agomelatine trial. Not much withdrawal can be expected but was nonetheless observed - concerning! Most are on ADs much longer. Absurd conclusions!